City Therapeutics’ Upsized IPO Raises $200M to Bring RNAi Drugs Beyond the Liver
City Therapeutics’ lead RNA interference therapy could become an alternative to blockbuster-selling anticoagulants. The company’s technology for designing RNAi drugs and delivering them to tissues throughout the body has already led to partnerships with Bausch + Lomb in eye diseases and Biogen in central nervous system disorders.
The Impending End of Cross-Subsidization
There is no single solution to the cross-subsidization problem. But here are some strategic actions that can make a health system’s economics more sustainable.
How AI Is Connecting MedTech’s Data Without Compromising Compliance
The connected, agent-ready enterprise is the model that wins, where compliance and intelligence operate together.
Rosarium Health Forms Home Modification Partnership with Anthem Medi-Cal
Rosarium Health partnered with Anthem Medi-Cal to provide home safety modifications for eligible members.
AI Biotech Iambic Gets $150M in IPO Cash for ‘Molecular Superintelligence’ Drug R&D
Iambic Therapeutics, an AI-enabled biotech company, will apply the IPO proceeds toward clinical development of its pipeline of internally discovered and wholly owned cancer drugs. Iambic also has R&D alliances with companies such as Bayer and AbbVie.